Variations in Serum IL-7 and 90K/Mac-2 Binding Protein (Mac-2 BP) Levels Analysed in Cohorts of HIV-1 Patients and Correlated with Clinical Changes Following Antiretroviral Therapy

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2001 Nov 13

PMID 11703373

Citations 10

Authors

E C Darcissac

V Vidal

X de la Tribonniere

Y Mouton

G M Bahr

Affiliations

Soon will be listed here.

Abstract

Serum levels of interleukin-7 (IL-7), a non-redundant cytokine that plays a crucial role in lymphopoiesis, are known to be elevated in HIV-1-infected subjects. To examine further the association between levels of IL-7, CD4+ cell counts and viraemia, we analysed these parameters in a large cohort of HIV-1 patients along with serum levels of 90K, a marker of disease severity but with no established involvement in lymphopoiesis. While IL-7 levels were only found to correlate with CD4+ cell counts, 90K levels presented strong correlations with both CD4+ cell numbers and with plasma viral loads (VLs). These correlations were maintained in patients naive to treatment with antiretrovirals (n = 38) but were abolished when the analysis was restricted to the group receiving highly active antiretroviral therapy (HAART, n = 82). Moreover, although 90K levels were significantly reduced in patients on HAART, IL-7 levels continued to be elevated despite successful treatment. The influence of HAART on the variations in these serum parameters was further assessed in a longitudinal study on 32 subjects. The HAART-induced decrease in VLs and increase in CD4+ counts were found to correlate with a reduced serum level of 90K and IL-7, respectively. Nevertheless, following a median period of 33 months of immunological and virological successful HAART, serum levels of IL-7 continued to be significantly elevated compared with those detected in healthy controls. These findings suggest that immunotherapy with IL-7, aimed to replenish T-cell stock in HAART-treated subjects, may have a limited impact on the process of immune reconstitution.

Citing Articles

HIV Infection: Shaping the Complex, Dynamic, and Interconnected Network of the Cytoskeleton.

Cabrera-Rodriguez R, Perez-Yanes S, Lorenzo-Sanchez I, Trujillo-Gonzalez R, Estevez-Herrera J, Garcia-Luis J Int J Mol Sci. 2023; 24(17).

PMID: 37685911 PMC: 10487602. DOI: 10.3390/ijms241713104.

Galectin 3-binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein.

Seki T, Kanagawa M, Kobayashi K, Kowa H, Yahata N, Maruyama K J Biol Chem. 2020; 295(11):3678-3691.

PMID: 31996371 PMC: 7076203. DOI: 10.1074/jbc.RA119.008703.

HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion.

Beitari S, Wang Y, Liu S, Liang C Viruses. 2019; 11(4).

PMID: 30935048 PMC: 6521621. DOI: 10.3390/v11040311.

M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner.

Wang Q, Zhang X, Han Y, Wang X, Gao G Sci Rep. 2016; 6:32736.

PMID: 27604950 PMC: 5015019. DOI: 10.1038/srep32736.

Sustained CD4 T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

Ellsworth S, Balmanoukian A, Kos F, Nirschl C, Nirschl T, Grossman S Oncoimmunology. 2014; 3(1):e27357.

PMID: 24790790 PMC: 4004618. DOI: 10.4161/onci.27357.

References

Briggs N, Natoli C, Tinari N, DEgidio M, Goedert J, Iacobelli S . A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses. 1993; 9(9):811-6. DOI: 10.1089/aid.1993.9.811. View

Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G . 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr (1988). 1993; 6(4):370-5. View

Ullrich A, Sures I, DEgidio M, Jallal B, Powell T, Herbst R . The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 1994; 269(28):18401-7. View

Vieira P, Lucian L, McNeil T, Burdach S, Murray R . Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med. 1995; 181(4):1519-26. PMC: 2191954. DOI: 10.1084/jem.181.4.1519. View

Casoli C, Lisa A, Magnani G, STARCICH R, Fiaccadori F, Bertazzoni U . Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users. J Med Virol. 1995; 45(2):203-10. DOI: 10.1002/jmv.1890450216. View

Powell T, Schreck R, McCall M, Hui T, Rice A, App H . A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol. 1995; 17(4):209-21. DOI: 10.1097/00002371-199505000-00003. View

Iacobelli S, Ullrich A, Tinari N, ORTONA L, Tamburrini E, DEgidio M . The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10(4):450-6. DOI: 10.1097/00042560-199512000-00008. View

Gattegno L, Gronowski S, Chaouche K, Ferriere F . Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection. Cell Adhes Commun. 1995; 3(3):179-85. DOI: 10.3109/15419069509081285. View

Andrews C, Koup R . The immunopathology of HIV infection. J Antimicrob Chemother. 1996; 37 Suppl B:13-25. DOI: 10.1093/jac/37.suppl_b.13. View

10.

Zeller J, McCain N, Swanson B . Immunological and virological markers of HIV-disease progression. J Assoc Nurses AIDS Care. 1996; 7(1):15-27. DOI: 10.1016/S1055-3290(96)80034-3. View

11.

Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C . Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996; 25(2):212-7. DOI: 10.1016/s0168-8278(96)80076-6. View

12.

Churchill D . Prognostic markers and surrogate markers of clinical progression in HIV infection. Int J STD AIDS. 1997; 8(9):552-6; quiz 557. DOI: 10.1258/0956462971920776. View

13.

Fusco O, Querzoli P, Nenci I, Natoli C, Brakebush C, Ullrich A . 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer. 1998; 79(1):23-6. DOI: 10.1002/(sici)1097-0215(19980220)79:1<23::aid-ijc5>3.0.co;2-y. View

14.

Vingerhoets J, Bisalinkumi E, Penne G, Colebunders R, Bosmans E, Kestens L . Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection. Immunol Lett. 1998; 61(1):53-61. DOI: 10.1016/s0165-2478(97)00162-4. View

15.

Fleury S, de Boer R, Rizzardi G, Wolthers K, Otto S, Welbon C . Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med. 1998; 4(7):794-801. DOI: 10.1038/nm0798-794. View

16.

Hellerstein M, Hanley M, Cesar D, Siler S, Papageorgopoulos C, Wieder E . Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999; 5(1):83-9. DOI: 10.1038/4772. View

17.

Trahey M, Weissman I . Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc Natl Acad Sci U S A. 1999; 96(6):3006-11. PMC: 15885. DOI: 10.1073/pnas.96.6.3006. View

18.

Bolotin E, Annett G, Parkman R, Weinberg K . Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999; 23(8):783-8. DOI: 10.1038/sj.bmt.1701655. View

19.

Hofmeister R, Khaled A, Benbernou N, Rajnavolgyi E, Muegge K, Durum S . Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 1999; 10(1):41-60. DOI: 10.1016/s1359-6101(98)00025-2. View

20.

Correale M, Giannuzzi V, Iacovazzi P, Valenza M, Lanzillotta S, Abbate I . Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res. 2000; 19(4C):3469-72. View